Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
I. Balaguer Vintró.
Estrategias en el control de los factores de riesgo coronario en la prevención primaria y secundaria.
Rev Esp Cardiol, 51 (1998), pp. 30-35
[2.]
S.M. Grundy, R. Pasternak, P. Greenland, S. Smith Jr., V. Fuster.
Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology.
J Am Coll Cardiol, 34 (1999), pp. 1348-1359
[3.]
R.H. Eckel.
Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association.
Circulation, 96 (1997), pp. 3248-3250
[4.]
G.F. Fletcher, G. Balady, S.N. Blair, J. Blumenthal, C. Caspersen, B. Chaitman, et al.
Statement on exercise: benefits and recommendations for physical activity programs for all Americans: a statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association.
Circulation, 94 (1996), pp. 857-862
[5.]
G. Assmann, P. Cullen, H. Schulte.
The Münster Heart Study (PROCAM). Results of follow-up at 8 years.
Eur Heart J, 19 (1998), pp. 2-11
[6.]
W.B. Kannel, D. McGee, T. Gordon.
A general cardiovascular risk profile: the Framingham Study.
Am J Cardiol, 38 (1976), pp. 46-51
[7.]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
JAMA, 285 (2001), pp. 2486-2497
[8.]
K.M. Anderson, P.W. Wilson, P.M. Odell, W.B. Kannel.
An updated coronary risk profile: a statement for health professionals.
Circulation, 83 (1991), pp. 356-362
[9.]
P.W. Wilson, R.B. D’Agostino, D. Levy, A.M. Belanger, H. Silbershatz, W.B. Kannel.
Prediction of coronary heart disease using risk factor categories.
Circulation, 97 (1998), pp. 1837-1847
[10.]
P.A. Wolf, R.B. D’Agostino, A.J. Belanger, W.B. Kannel.
Probablity of stroke: a risk profile from the Framingham study.
Stroke, 22 (1991), pp. 312-318
[11.]
J.M. Murabito, R.B. D’Agostino, H. Silbershatz, P.W. Wilson.
Intermittent claudication: a risk profile from the Framingham Heart study.
Circulation, 96 (1997), pp. 44-49
[12.]
D. Wood, G. De Backer, O. Faergeman, I. Graham, G. Mancia, K. Pyörälä.
togheter with members of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.
Atherosclerosis, 140 (1998), pp. 199-270
[13.]
I.U. Haq, P.R. Jackson, W.W. Yeo, L.E. Ramsay.
Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease.
Lancet, 346 (1995), pp. 1467-1471
[14.]
L.E. Ramsay, I.U. Haq, P.R. Jackson, W.W. Yeo, D.M. Pickin, J.N. Payne.
Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table.
Lancet, 348 (1996), pp. 387-388
[15.]
British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice.
Heart, 80 (1998), pp. 1-29
[16.]
Control de la colesterolemia en España, 2000. Un instrumento para la prevención cardiovascular.
Clin Invest Arterioscler, 12 (2000), pp. 125-152
[18.]
World Health Organization, International Society of Hypertension. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Guidelines subcommittee.
J Hypertens, 17 (1999), pp. 151-183
[19.]
Evidencias clinicoexperimentales y recomendaciones para el tratamiento de la hiperlipidemia en pacientes con cardiopatía isquémica.
Clin Invest Arterioscler, 6 (1994), pp. 103-111
[20.]
I.U. Haq, L.E. Ramsay, D.M. Pickin, W.W. Yeo, P.R. Jackson, J.N. Payne.
Lipid-lowering for prevention of coronary heart disease: what policy now?.
Clin Sci (Lond), 91 (1996), pp. 399-413
[21.]
R.B. D’Agostino, M.W. Russell, D.M. Huse, R.C. Ellison, H. Silbershatz, P.W. Wilson, et al.
Primary and subsequent coronary risk appraisal: new results from the Framingham study.
Am Heart J, 139 (2000), pp. 272-281
[22.]
A. Menotti, P.E. Puddu, M. Lanti.
Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study.
Eur Heart J, 21 (2000), pp. 365-370
[23.]
A. Menotti, M. Lanti, P.E. Puddu, D. Kromhout.
Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart.
Heart, 84 (2000), pp. 238-244
[24.]
C.E. Lloyd, L.H. Kuller, D. Ellis, D.J. Becker, R.R. Wing, T.J. Orchard.
Coronary artery disease in IDDM: gender differences in risk factors but not risk.
Arterioscler Thromb Vasc Biol, 16 (1996), pp. 720-726
[25.]
P.W. Wilson.
Diabetes mellitus and coronary heart disease.
Am J Kidney Dis, 32 (1998), pp. 89-100
[26.]
Sociedad Española de Arteriosclerosis y Sociedad Española de Diabetes. Dislipemia diabética. Documento de Consenso de la Sociedad Española de Arteriosclerosis y la Sociedad Española de Diabetes.
Clin Invest Arterioscler, 10 (1998), pp. 55-64
[27.]
B. Janand-Delenne, B. Savin, G. Habib, M. Bory, P. Vague, V. Lassmann-Vague.
Silent myocardial ischemia in patients with diabetes: who to screen.
Diabetes Care, 22 (1999), pp. 1396-1400
[28.]
S.M. Haffner, S. Lehto, T. Rönnemaa, K. Pyörälä, M. Laakso.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med, 339 (1998), pp. 229-234
[29.]
American Diabetes Association. Management of dyslipidemia in adults with diabetes.
Diabetes Care, 25 (2002), pp. 74-77
[30.]
National Institutes of Health, National Heart, Lung, and Blood Institute, (1998),
[31.]
S.N. Blair, H.W. Kohl III, C.E. Barlow, R.S. Paffenbarger Jr., L.W. Gibbons, C.A. Macera.
Changes in physical fitness and all-cause mortality: a prospective study of healthy and unhealthy men.
JAMA, 273 (1995), pp. 1093-1098
[32.]
G.F. Fletcher.
How to implement physical activity in primary and secondary prevention: a statement for healthcare professionals from the Task Force on Risk-reduction, American Heart Association.
Circulation, 96 (1997), pp. 355-357
[33.]
C. Martín Dolz, R. Hernández Ribas, J.E. Rodes Rojo.
La cardiopatía isquémica y los factores psiquiátricos.
Clin Invest Arterioscler, 12 (2000), pp. 285-296
[34.]
G. Assmann, H. Schulte, H. Funke, A. Von Eckardstein.
The emergence of triglycerides as a significant independent risk factor in coronary artery disease.
Eur Heart J, 19 (1998), pp. 8-14
[35.]
V. Manninen, J.K. Huttunen, O.P. Heinonen, L. Tenkanen, M.H. Frick.
Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinky Heart Study.
Am J Cardiol, 63 (1989), pp. 42-47
[36.]
G.M. Reaven.
Role of insulin resistance in human disease.
Diabetes, 37 (1988), pp. 1595-1607
[37.]
R.A. DeFronzo, E. Ferrannini.
Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.
Diabetes Care, 14 (1991), pp. 173-194
[38.]
H.N. Ginsberg.
Insulin resistance and cardiovascular disease.
J Clin Invest, 106 (2000), pp. 453-458
[39.]
J. Yip, F.S. Facchini, G.M. Reaven.
Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease.
J Clin Endocrinol Metab, 83 (1998), pp. 2773-2776
[40.]
T.C. Fagan, P.C. Deedwania.
The cardiovascular dysmetabolic syndrome.
Am J Med, 105 (1998), pp. 77-82
[41.]
J.M. Mostaza, G.L. Vega, P. Snell, S.M. Grundy.
Abnormal metabolism of free fatty acids in hypertriglyceridemic men: apparent insulin resistance of adipose tissue.
J Intern Med, 243 (1998), pp. 265-274
[42.]
X. Pintó, M.A. Vilaseca, N. García-Giralt, I. Ferrer, M. Palá, J.F. Meco, et al.
Homocysteine and the MTHFR 677C(T allele in premature coronary artery disease. Case control and family studies.
Eur J Clin Invest, 31 (2001), pp. 24-30
[43.]
M.R. Malinow, A.G. Bostom, R.M. Krauss.
Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association.
Circulation, 99 (1999), pp. 178-182
[44.]
J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A. Ross Lorimer, P.W. Macfarlane, et al.
for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The WOS study.
N Engl J Med, 333 (1995), pp. 1301-1307
[45.]
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II).
JAMA, 269 (1993), pp. 3015-3023
Copyright © 2002. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.